Anaplastic Thyroid Carcinoma

Bibliography

  1. Sherman, E. J. et al. Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial. The Lancet Oncology 24, 175–186 (2023).
  2. Maurer, E. et al. Mutation-based, short-term ‘neoadjuvant’ treatment allows resectability in stage IVB and C anaplastic thyroid cancer. Eur Arch Otorhinolaryngol (2023) doi:10.1007/s00405-023-07827-y.
  3. Lorimer, C. et al. Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer - Real-World Outcomes From UK Centres. Clin Oncol (R Coll Radiol) 35, e60–e66 (2023).
  4. Jungels, C., Pita, J. M. & Costante, G. Anaplastic thyroid carcinoma: advances in molecular profiling and targeted therapy. Curr Opin Oncol 35, 1–9 (2023).
  5. Yuan, J. & Guo, Y. Targeted Therapy for Anaplastic Thyroid Carcinoma: Advances and Management. Cancers (Basel) 15, 179 (2022).
  6. Subbiah, V. et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol 33, 406–415 (2022).
  7. Ragusa, F. et al. Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer. Int J Mol Sci 23, 5731 (2022).
  8. Luo, Y. et al. Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma. Front Endocrinol (Lausanne) 13, 859013 (2022).
  9. Lee, J.-S. et al. Prognosis of Anaplastic Thyroid Cancer with Distant Metastasis. Cancers (Basel) 14, 5784 (2022).
  10. Jannin, A. et al. Anaplastic Thyroid Carcinoma: An Update. Cancers (Basel) 14, 1061 (2022).
  11. Huang, D., Zhang, J., Zheng, X. & Gao, M. Efficacy and Safety of Lenvatinib in Anaplastic Thyroid Carcinoma: A Meta-Analysis. Front Endocrinol (Lausanne) 13, 920857 (2022).
  12. Dong, W. et al. Conditional Survival Rate Estimates for Anaplastic Thyroid Cancer Beyond the First Year: An Analysis of SEER Data (2004 to 2019). Thyroid (2022) doi:10.1089/thy.2022.0339.
  13. Chen, Y. H. et al. Prior thyroid and non-thyroid cancer history do not significantly alter overall survival in patients diagnosed with anaplastic thyroid carcinoma. Thyroid (2022) doi:10.1089/thy.2022.0350.
  14. Xiang, J., Wang, Z., Sun, W. & Zhang, H. A relook at the 8th edition of the AJCC TNM staging system of anaplastic thyroid carcinoma: A SEER-based study. Clin Endocrinol (Oxf) 94, 700–710 (2021).
  15. Zhang, H., Zhao, Y.-C., Wu, Q., Wang, L. & Sun, S. The prognostic value of lymph node metastasis and the eighth edition of AJCC for patients with anaplastic thyroid cancer. Clin Endocrinol (Oxf) 95, 498–507 (2021).
  16. Rocha, M. L., Schmid, K. W. & Czapiewski, P. The prevalence of DNA microsatellite instability in anaplastic thyroid carcinoma - systematic review and discussion of current therapeutic options. Contemp Oncol (Pozn) 25, 213–223 (2021).
  17. Kim, H. J., Chang, H.-S. & Ryu, Y. H. Prognostic Role of Pre-Treatment [18F]FDG PET/CT in Patients with Anaplastic Thyroid Cancer. Cancers (Basel) 13, 4228 (2021).
  18. Abe, I. & Lam, A. K.-Y. Anaplastic thyroid carcinoma: Updates on WHO classification, clinicopathological features and staging. Histol Histopathol 36, 239–248 (2021).
  19. Maniakas, A. et al. Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. JAMA Oncology 6, 1397–1404 (2020).
  20. Lin, B. et al. The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis. Am J Transl Res 11, 5888–5896 (2019).
  21. Subbiah, V. et al. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clin Oncol 36, 7–13 (2018).
  22. Ghossein, R. A., Katabi, N. & Fagin, J. A. Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression. J Clin Endocrinol Metab 98, E1414-1421 (2013).
  23. Thomas, C. G. & Buckwalter, J. A. Cancer of the thyroid. Adv Surg 10, 245–285 (1976).
  24. Smallridge, R. C. & Copland, J. A. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol) 22, 486–497 (2010).
19 / 19